Related by context. All words. (Click for frequent words.) 66 Zerenex 64 mipomersen 63 phase IIa clinical 63 ISIS # 63 lomitapide 63 Epanova 62 Archexin 62 eprotirome 62 JAK inhibitor 62 Phenoptin 62 Huntexil 62 PREOS 61 Anturol TM 61 PROVENGE sipuleucel T 61 PEG PAL 61 phase IIb 61 Tyrima 61 INCB# [002] 61 elotuzumab 60 Azedra 60 MEK inhibitor RDEA# 60 RSD# oral 60 QNEXA 60 liprotamase 60 mixed dyslipidemia 60 Mipomersen 60 Ophena TM 60 torezolid phosphate 60 registrational 60 regorafenib 60 teduglutide 60 CoFactor 60 romidepsin 60 6R BH4 60 OHR/AVR# 60 BAY #-# 60 APF# 60 triglyceride lowering 59 NGX# 59 Phase 2a trial 59 CaPre TM 59 R#/MEM # 59 tesetaxel 59 Marqibo 59 picoplatin 59 metaglidasen 59 axitinib 59 DPP4 inhibitor 59 thymalfasin 59 oral taxane 59 Acapodene 59 orBec 59 RDEA# 59 linaclotide 59 nebivolol 59 PS# [001] 59 tivozanib 59 Zerenex ™ 59 Phase 2a 59 enzastaurin 59 rNAPc2 59 Androxal 59 Icatibant 59 anti arrhythmic 59 ruxolitinib 58 SRT# [003] 58 TH# [003] 58 AEGR 58 IMA# 58 GALNS 58 EOquin 58 tezampanel 58 teriflunomide 58 ambrisentan 58 PXD# 58 anticancer compound 58 Phase 2b clinical 58 OvaRex ® MAb 58 Rebif ® 58 Triolex 58 Serdaxin 58 NEBIDO 58 Technosphere Insulin 58 tecarfarin 58 Dextofisopam 58 Genz # 58 Phase 2b trial 58 bardoxolone 58 PRT# 58 Plenaxis TM 58 AZILECT ® 58 SILENOR 58 bicifadine 58 Targretin 58 Onrigin 58 rhThrombin 58 Phase IIa trial 58 Corlux 58 Amigal 58 PSN# [002] 58 pivotal Phase III 58 alvespimycin 58 fenofibric acid 58 BrachySil 58 microplasmin 58 bucindolol 58 LibiGel ® 58 Xanafide 58 alogliptin 58 Clonicel 58 KNS # 58 GATTEX 58 Phase 1b trial 58 ruboxistaurin 58 oral ridaforolimus 58 FOLOTYN ® 58 HQK 58 alvimopan 58 MAGE A3 ASCI 58 DPX Survivac 58 Troxatyl 58 DCCR 57 NUVIGIL 57 NP2 Enkephalin 57 CYCLOSET 57 omacetaxine 57 atrasentan 57 blinatumomab 57 ANCHOR trial 57 Phase IIa trials 57 Vilazodone 57 tanespimycin 57 amrubicin 57 ProSavin 57 L BLP# 57 efficacy tolerability 57 TRV# [001] 57 PDE4 inhibitor 57 Celacade TM technology 57 velafermin belinostat 57 Phase 2b study 57 Firazyr 57 Phase 2b clinical trials 57 investigational drug 57 ganetespib 57 Anturol ® 57 Phase Ib 57 fidaxomicin 57 registrational trial 57 Bronchitol 57 Pimavanserin 57 VIAject 57 lasofoxifene 57 ILUVIEN ® 57 phase IIb clinical 57 Darusentan 57 CR# vcMMAE 57 sapacitabine 57 bazedoxifene 57 IL# PE#QQR 57 eltrombopag 57 vilazodone 57 cangrelor 57 lurasidone 57 Panzem R 57 Asentar 57 Ostarine 57 ISTODAX 57 Ereska 57 Rezular 57 dimebon 57 HoFH 57 CORLUX 57 neratinib 57 DU #b 57 KRN# 57 Plicera 57 Memryte 57 Northera 57 Naproxcinod 57 Zensana TM 57 PRTX 57 severe hypercholesterolemia 57 investigational compound 57 dalbavancin 57 Anturol 57 dexpramipexole 56 avanafil 56 Bicifadine 56 oral prodrug 56 brivaracetam 56 Civacir 56 Amrubicin 56 Nasulin 56 Phase 2a clinical 56 pradefovir 56 Entereg alvimopan 56 ATL# [001] 56 palifosfamide 56 Folotyn 56 FACTIVE R gemifloxacin 56 phase IIb trial 56 urocortin 2 56 glufosfamide 56 Phase IIb clinical 56 Ferumoxytol 56 Phase 2b 56 Fodosine 56 LEP ETU 56 Aurexis 56 tamibarotene 56 crofelemer 56 albinterferon alfa 2b 56 GATTEX ® 56 refractory gout 56 Phase IIa clinical 56 Soliris TM eculizumab 56 DR Cysteamine 56 pralatrexate 56 obatoclax 56 Phase III clinical 56 varespladib 56 Krystexxa 56 INCB# [001] 56 tiapamil 56 ZYBRESTAT 56 bifeprunox 56 betrixaban 56 tesmilifene 56 ixabepilone 56 HuMax EGFr 56 SILENOR TM 56 Voraxaze 56 pafuramidine 56 Androxal TM 56 arzoxifene 56 Phase Ib study 56 HZT 56 belinostat 56 Viprinex TM 56 atacicept 56 CTAP# Capsules 56 investigational therapies 56 AP# [003] 56 otelixizumab 56 Certriad 56 Serdaxin ® 56 subcutaneous formulation 56 TriRima 56 Dyloject TM 56 EOquin TM 56 MAA submission 56 LAF# 56 SinuNase 56 Muraglitazar 56 oral gallium 56 Stedivaze 56 Phase IIb 56 hoFH 56 topical NSAID 56 Zybrestat 56 Catena ® 56 Phase III 56 diabetic neuropathic pain 56 EDEMA3 56 cannabinor 56 OncoVEX GM CSF 56 Panzem 56 preclinically 56 TOCOSOL Paclitaxel 56 Adlea 56 ThGRF 56 BCX# 56 vidofludimus 56 relapsed multiple myeloma 56 TBC# 56 pomalidomide 56 RSD# 56 HspE7 55 Oral NKTR 55 Onconase 55 midstage clinical 55 NB S# 55 iloperidone 55 forodesine 55 PANVAC VF 55 Viramidine 55 BEMA Buprenorphine 55 edoxaban 55 Omigard 55 PDX pralatrexate 55 Phase 2b monotherapy 55 dose cohort 55 riociguat 55 Amplimexon 55 Cleviprex TM clevidipine 55 Phase IIIb clinical 55 MDV# 55 favorable pharmacokinetic profile 55 Genasense ® oblimersen 55 Neurodex 55 Proxinium TM 55 IND submission 55 milnacipran 55 balsalazide tablet 55 ozarelix 55 Arcalyst 55 urate lowering 55 eritoran 55 EFAPROXYN 55 Cloretazine R VNP#M 55 placebo controlled Phase 55 oxypurinol 55 fostamatinib 55 Menerba 55 anidulafungin 55 EDEMA4 55 Enjuvia 55 PHX# 55 Fx #A 55 BYDUREON 55 glucokinase activator 55 MoxDuo IR 55 heterozygous FH 55 OMAPRO 55 sodium glucose cotransporter 55 rosuvastatin calcium 55 dirucotide 55 Diamyd R 55 BEMA Granisetron 55 NDA resubmission 55 Rasilez 55 Zemplar Capsules 55 ularitide 55 compound INCB# 55 saxagliptin 55 PREOS R 55 dose escalation Phase 55 ADVEXIN 55 Telatinib 55 Stalevo 55 insulin sensitizers 55 ospemifene 55 velafermin 55 T Pred 55 Contrave 55 MGCD# [001] 55 LDL lowering 55 leading oral taxane 55 ocrelizumab 55 CA4P 55 Evoltra 55 mifamurtide 55 ELND# 55 PSN# [001] 55 Ceflatonin 55 seliciclib CYC# 55 DDP# 55 ponatinib 55 AERx iDMS 55 ANAVEX #-# [003] 55 CRMD# 55 sunitinib malate 55 Capesaris 55 BLA filing 55 IRX 2 55 Preos 55 Aclidinium 55 GSK# [002] 55 SARMs 55 Gattex 55 eculizumab 55 Azedra TM 55 naproxcinod 55 olmesartan 55 IV APAP 55 Phase 1b 55 Chrysalin 55 Viprinex 55 tolerability profile 55 Phase Ia 55 velaglucerase alfa 55 Pivotal Phase III 55 Phase IIb trials 55 Afrezza 55 NeuVax 55 carfilzomib 55 Byetta LAR 55 Androxal ® 54 oxymorphone ER 54 CIMZIA ™ 54 EndoTAG TM -1 54 APEX PD 54 aleglitazar 54 Cloretazine R 54 lumiliximab 54 dyslipidemia 54 novel oral anticoagulant 54 Fibrillex TM 54 Oracea TM 54 pitavastatin 54 Imagify 54 PRX # 54 valopicitabine 54 muraglitazar 54 myelofibrosis 54 Zelrix 54 ACAPODENE 54 Tarceva TM 54 Flutiform TM 54 tramiprosate 54 docetaxel Taxotere R 54 AEG# 54 CAPHOSOL 54 TRO# 54 fluvastatin 54 Frova ® 54 Locteron ® 54 confirmatory Phase III 54 CDP# 54 PEG SN# 54 REOLYSIN ® 54 Bepreve 54 AFRESA 54 vaginally administered lidocaine 54 PLK1 SNALP 54 Silodosin 54 Phase Ib clinical 54 bapineuzumab 54 Alzhemed TM 54 MYDICAR 54 vosaroxin 54 Elagolix 54 Phase III trials 54 Daclizumab 54 custirsen 54 Cycloset 54 HuMax CD# 54 Evoltra TM 54 clofarabine 54 Phase IIa 54 Leukine 54 Nuedexta 54 pharmacokinetics PK 54 Alpharadin 54 Ixempra 54 Tekamlo 54 Aptivus 54 Solesta 54 Myocet 54 multicenter Phase III 54 celgosivir 54 Pruvel 54 Ceplene 54 histamine dihydrochloride 54 intravenous formulation 54 ataluren 54 perifosine 54 Medidur FA 54 PhosLo 54 tasocitinib 54 Vicinium TM 54 linagliptin 54 MBP# [001] 54 Surfaxin LS 54 Evoltra ® 54 Carfilzomib 54 Ketotransdel 54 AQ4N 54 relapsed refractory multiple myeloma 54 ZYBRESTAT fosbretabulin 54 budesonide MMX 54 Clolar ® 54 Phase III clinical trials 54 Galvus 54 confirmatory clinical 54 novel histone deacetylase 54 selective androgen receptor modulator 54 maximally tolerated dose 54 faropenem 54 vorinostat 54 Avanafil 54 Empatic 54 voclosporin 54 Ambrisentan 54 BEMA TM Fentanyl 54 ELACYT 54 Nebido 54 CEQ# 54 Ventavis 54 Zensana 54 methylnaltrexone 54 AFREZZA 54 Orapred ODT 54 NPSP# 54 MACUGEN 54 Aplidin 54 Rescula 54 rolofylline 54 TAXUS Element Stent System 54 JANUVIA 54 Atiprimod 54 ILLUMINATE 54 Vectibix panitumumab 54 Diamyd ® 54 vildagliptin 54 Hyphanox 54 Phenserine 54 DPP4 54 pegloticase 54 Cinquil 54 peginesatide 54 maribavir 54 Exherin TM 54 active comparator 54 casopitant 54 pharmacokinetic PK 54 phase IIa 54 SIMCOR 54 Balaglitazone 54 PrevOnco 54 apixaban 54 eniluracil 54 liposomal formulation 54 ToGA 54 Genasense R oblimersen 54 darapladib 54 TRISENOX 54 PI3K/Akt pathway inhibitor 54 pramlintide 54 LY# [003] 54 virus HCV protease inhibitor 54 FM VP4 54 daclizumab 54 schizophrenia CIAS 54 Iluvien ® 54 abiraterone acetate 54 Cinacalcet HCl 54 lintuzumab 54 UPLYSO 54 vandetanib 54 Nexavar ® 54 Symadex 54 FOLOTYN 54 ceftaroline 53 nalbuphine ER 53 mertansine 53 MICARDIS ® 53 Dacogen injection 53 lorvotuzumab mertansine 53 Pirfenidone 53 talactoferrin 53 aclidinium bromide 53 Pyridorin 53 deforolimus 53 Cangrelor 53 Personalized Immunotherapy 53 LEVADEX ™ 53 aclidinium 53 Reverset 53 AGGRASTAT ® 53 Zenvia 53 EGS# 53 ARCOXIA 53 epigenetic therapies 53 febuxostat 53 huC# DM4 53 AzaSite Plus 53 ALTU 53 Phase Ib II 53 Panzem R NCD 53 Kuvan 53 AZILECT R 53 rALLy 53 Lu AA# 53 bosutinib 53 sorafenib Nexavar 53 VEGF Trap 53 Guanilib 53 elacytarabine 53 Oncogenex 53 TRIOLEX 53 Alocrest 53 incyclinide 53 Ranexa 53 Ceflatonin ® 53 Phase 1b clinical 53 vernakalant 53 Benlysta belimumab 53 trodusquemine 53 Qnexa 53 Teflaro 53 TriLipix 53 Desmoteplase 53 Insegia 53 ZACTIMA 53 ELIQUIS 53 Albuferon 53 BLA submission 53 mesylate tablets 53 Omacetaxine 53 voreloxin 53 Sulonex 53 nonclinical studies 53 Phase IIb clinical trials 53 NVA# 53 EVIZON 53 StemEx R 53 ELADUR 53 crizotinib PF # 53 INC# 53 INKP 53 Pazopanib 53 satraplatin 53 BrachySil TM 53 E2F Decoy 53 Trizytek 53 ecallantide 53 afatinib 53 vascular disrupting agent 53 glitazones 53 MEND CABG 53 ofatumumab 53 pain palliation 53 L MTP PE 53 Anavex #-# 53 Vernakalant 53 RSR# 53 Apixaban 53 regadenoson 53 pivotal Phase 53 2 methoxyestradiol 53 Egrifta 53 cutaneous T cell 53 Perforomist ™ Inhalation Solution 53 exenatide once 53 tolevamer 53 HuMax CD4 53 Milnacipran 53 pioglitazone HCl 53 pharmacokinetic PK study 53 opioid induced bowel dysfunction 53 azficel T 53 TREDAPTIVE 53 apremilast 53 IIa trial 53 lubiprostone 53 MOZOBIL 53 ONCONASE 53 OvaRex 53 phase Ib 53 TRANSDUR Bupivacaine 53 darusentan 53 Dapagliflozin 53 EXPAREL ™ 53 clinical trials Multikine 53 Augment Injectable 53 tolerability profiles 53 BNC# 53 Afresa 53 rosuvastatin 53 calcitonin 53 AOD# [002] 53 Fibrillex 53 preclinical efficacy 53 MLN# 53 elagolix 53 Xinlay 53 MAP# 53 IIa clinical 53 MEND CABG II 53 ZEGERID Capsules 53 LCP AtorFen 53 TELCYTA 53 Riquent 53 GLASSIA 53 SCOLR Pharma 53 CINQUIL 53 TRILIPIX 53 Aryplase 53 investigational humanized monoclonal antibody 53 tolerability 53 aliskiren 53 oral cladribine 53 randomized Phase 53 LibiGel 53 NeuroSTAT ® 53 rALLy clinical trial 53 Prostate AdenoCarcinoma Treatment 53 ALD# 53 Toraymyxin TM 53 Stelara 53 AVERROES 53 Exelon Patch 53 SinuNase TM 53 pharmacodynamic 53 Kynapid 53 Safinamide 53 retigabine 53 zanolimumab 53 MyVax personalized immunotherapy 53 exenatide LAR 53 JAK inhibitors 53 ARIKACE ™ 53 GLP toxicology studies 53 Acetavance 53 XmAb# 53 PROMACTA 53 topical formulations 53 CINTREDEKIN BESUDOTOX 53 Chemophase 53 Cloretazine 52 ALGRX 52 VIAject R 52 AZX# 52 SNT MC# 52 BENLYSTA 52 pramlintide metreleptin 52 adecatumumab 52 mTOR inhibitor 52 Proellex TM 52 phase 2a 52 MK #A [001] 52 panitumumab 52 oral talactoferrin 52 sargramostim 52 CB2 selective receptor agonist 52 LibiGel Phase III 52 Ticagrelor 52 MERLIN TIMI 52 Tavocept 52 Ceflatonin R 52 ORMD 52 evaluating bafetinib 52 visilizumab 52 Cloretazine ® 52 lapatinib Tykerb 52 reslizumab 52 Pemetrexed 52 Erbitux cetuximab 52 olaparib 52 Cardio Vascu Grow 52 CIMZIA TM 52 aflibercept 52 Omthera 52 Liprostin 52 Annamycin 52 PEG Interferon lambda 52 MAXY G# 52 ONCONASE R 52 SCH # 52 Torisel 52 AVANDIA 52 Celgene Revlimid 52 Merck Januvia 52 postoperative ileus 52 PEP# [003] 52 iSONEP 52 SEPET TM 52 oral antidiabetic 52 Xarelto rivaroxaban 52 Topical Interferon Alpha 2b 52 Vidaza azacitidine 52 Virulizin R 52 rALLy trial 52 pharmacodynamic effects 52 Allovectin 7 R 52 liraglutide 52 ADX# 52 Phase IIB 52 indiplon capsules 52 hypoxia activated prodrug 52 AeroLEF TM 52 OvaRex R 52 denufosol 52 Zenpep 52 Bydureon 52 systemic immunosuppressive drugs 52 Cimzia TM 52 REMINYL ® 52 Onbrez Breezhaler 52 Dasatinib 52 pharmacodynamic PD 52 Linjeta ™ 52 ENRICH trial 52 Biologics License Application BLA 52 baminercept 52 pseudobulbar affect PBA 52 oritavancin 52 Phase #/#a trial 52 galiximab 52 metformin sulfonylurea 52 investigational hepatitis C 52 acyclovir Lauriad R 52 YONDELIS 52 RE LY 52 Pennsaid R 52 Linjeta 52 Xibrom 52 Prestara 52 Traficet EN 52 TELINTRA 52 investigational compounds 52 Phase IIIb 52 teplizumab 52 Saxagliptin 52 Degludec 52 cancer immunotherapies 52 Perifosine 52 SILENOR ™ 52 pazopanib 52 RG# [001] 52 brentuximab vedotin 52 Orathecin 52 Silenor ® 52 Orazol 52 inhaled AAT 52 lucinactant 52 valsartan 52 Spiegelmer ® 52 GSK# [001] 52 temsirolimus 52 FOSRENOL 52 MNTX 52 investigational pan BCR 52 ASA# 52 GLPG# 52 TASQ 52 THALOMID 52 Phase #b/#a 52 Synavive 52 Urocidin 52 ZOLINZA 52 Q#IR 52 Zolinza 52 ThermoDox ® 52 INCB# [003] 52 Cellegesic 52 safinamide 52 vicriviroc 52 NEXTERONE 52 prGCD 52 cutaneous T 52 SPP# [001] 52 Celebrex celecoxib 52 oral formulation 52 FavId 52 Satraplatin 52 StaphVAX 52 Cutanea 52 AZD# 52 Phase IIb trial 52 tezampanel NGX# 52 Promacta 52 OPAXIO 52 MB# [004] 52 PMA submission 52 hepatitis C protease inhibitor 52 canakinumab 52 BYETTA ® 52 farletuzumab 52 indacaterol 52 Vidaza 52 palifosfamide Zymafos TM 52 CANCIDAS 52 direct renin inhibitor 52 blinded randomized placebo controlled 52 EP #R 52 TACI Ig 52 rilonacept 52 cancer neuroendocrine tumor 52 Trexima 52 TMC# [002] 52 gepirone ER 52 perampanel 52 PNP inhibitor 52 LY# [002] 52 BRIM2 52 Fampridine SR 52 LCP Tacro 52 Phase #b/#a trial 52 Golimumab 52 Sym# 52 lymphoma CTCL 52 Zavesca R 52 Zenvia ™ 52 Celator 52 double blinded placebo 52 APD# 52 Quinamed 52 ALVESCO HFA 52 Restanza 52 exenatide 52 Complete Response 52 Trofex TM 52 thorough QT 52 Phase 1a clinical 52 alfimeprase 52 ThermoDox 52 telcagepant 52 BAL# [002] 52 vemurafenib 52 antiplatelet agent 52 Bystolic 52 OMS#HP 52 oral salmon calcitonin 52 neurogenic orthostatic hypotension 52 Factor VIIa 52 Exforge 52 IMPACT IMmunotherapy 51 Actemra 51 Biologics License Application 51 Atrasentan 51 Phase 2a clinical trials 51 Cand5 51 midstage trials 51 Endeavor DES 51 ACOMPLIA R 51 QAB# 51 NATRECOR R 51 CRx 51 Alvesco R 51 metastatic HRPC 51 Nexavar sorafenib 51 CA9 SCAN 51 Zelapar 51 Exenatide LAR 51 immunotherapeutic vaccine 51 Topiramate 51 LE SN# 51 cediranib 51 BRAF inhibitor 51 Bezielle 51 TOLAMBA 51 ustekinumab 51 R sorafenib tablets 51 HGS# 51 Relovair 51 lixisenatide 51 evaluating tivozanib 51 zileuton CR 51 Neuradiab 51 Hsp# inhibitor 51 Trofex 51 oral deforolimus 51 pharmacokinetic PK profile 51 MK #B 51 Iloperidone 51 phase IIb study 51 Lupuzor 51 refractory Hodgkin lymphoma 51 Itopride 51 ZoMaxx 51 Phase III Clinical Trials 51 ridaforolimus 51 AZOR 51 oral anticoagulant 51 Nuvion 51 Tesofensine 51 rivaroxaban 51 Solorel 51 castrate resistant prostate cancer 51 Teriflunomide 51 Glufosfamide 51 Saforis 51 dexanabinol 51 Indaflex TM 51 metastatic hormone refractory 51 CVac 51 IPLEX 51 clinical trial 51 Zenvia Phase III 51 CLIRS trial 51 Increlex ® 51 Telavancin 51 Cerovive 51 placebo controlled clinical 51 Pivotal Phase 51 Focalin XR 51 olanzapine Zyprexa 51 Intermezzo R 51 Rasagiline 51 secondary efficacy endpoints 51 efficacy endpoint 51 Cetrorelix 51 panitumumab Vectibix 51 LymphoStat B 51 budesonide foam 51 Veronate 51 nab paclitaxel 51 Vivitrex 51 lumiracoxib 51 GRN# 51 Altastaph 51 Xcytrin R 51 Fablyn 51 PTH analogue 51 Telaprevir 51 diarrhea predominant irritable